Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.59 and traded as high as $5.37. Achieve Life Sciences shares last traded at $5.35, with a volume of 111,199 shares traded.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on ACHV shares. Oppenheimer dropped their target price on Achieve Life Sciences from $18.00 to $11.00 and set an "outperform" rating for the company in a research report on Monday, May 13th. Jonestrading assumed coverage on Achieve Life Sciences in a research note on Wednesday, April 17th. They issued a "buy" rating and a $20.00 price target on the stock. Finally, Lake Street Capital decreased their price target on Achieve Life Sciences from $19.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, March 5th.
Check Out Our Latest Analysis on Achieve Life Sciences
Achieve Life Sciences Price Performance
The stock has a market capitalization of $180.63 million, a PE ratio of -4.08 and a beta of 1.34. The company has a 50 day moving average price of $4.84 and a 200-day moving average price of $4.59.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). As a group, equities analysts anticipate that Achieve Life Sciences, Inc. will post -1.04 earnings per share for the current year.
Institutional Investors Weigh In On Achieve Life Sciences
Several hedge funds have recently made changes to their positions in the company. Raymond James & Associates boosted its position in shares of Achieve Life Sciences by 6.0% during the fourth quarter. Raymond James & Associates now owns 154,829 shares of the biopharmaceutical company's stock valued at $638,000 after buying an additional 8,729 shares during the last quarter. Madison Park Capital Advisors LLC purchased a new stake in shares of Achieve Life Sciences during the fourth quarter valued at $41,000. Vanguard Group Inc. boosted its position in shares of Achieve Life Sciences by 56.6% during the first quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company's stock valued at $4,311,000 after buying an additional 342,731 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Achieve Life Sciences during the first quarter valued at $59,000. Finally, Propel Bio Management LLC purchased a new stake in shares of Achieve Life Sciences during the first quarter valued at $11,149,000. 33.52% of the stock is currently owned by institutional investors.
Achieve Life Sciences Company Profile
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Further Reading
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
